Boston Scientific has received FDA approval to bring to market the 2.25 mm PROMUS Everolimus-Eluting Coronary Stent System, and the company is planning to make it immediately available. The PROMUS line is now available in diameters from 2.25 mm to 4.0 mm and lengths from 8 mm to 28 mm.
The PROMUS Stent features a thin-strut, open-cell design to allow for excellent flexibility and conformability in the vessel. The low-profile stent and catheter tip help enhance deliverability, especially in small vessels.
Data from clinical studies have shown that an estimated 10 percent of patients undergoing percutaneous coronary interventions have small vessels (<2.5 mm). The 2.25 mm PROMUS Stent joins the 2.25 mm ION™ Paclitaxel-Eluting Platinum Chromium Stent as the Company's approved drug-eluting stenting options for small vessels. The PROMUS Stent is a private-labeled XIENCE V® Everolimus-Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific. PROMUS is a trademark of Boston Scientific Corporation or its affiliates. XIENCE V is a trademark of the Abbott Laboratories group of companies. The SPIRIT clinical trials are sponsored by Abbott.
Press release: Boston Scientific Announces FDA Approval and U.S. Launch of PROMUS® 2.25 mm Everolimus-Eluting Coronary Stent System …
Product page: PROMUS® Everolimus-Eluting Coronary Stent System …
